Cocrystal Pharma Appoints Carol L. Brosgart to Board

What Happened Cocrystal Pharma, Inc. (COCP) filed a Form 8-K on August 17, 2026 to disclose that it has appointed Carol L. Brosgart, MD to its Board of Directors. The company furnished a press release announcing the appointment as Exhibit 99.1 to the filing and made the disclosure under Regulation FD.

Key Details

• Company: Cocrystal Pharma, Inc. (COCP).
• Event: Appointment of Carol L. Brosgart, MD to the Board of Directors.
• Filing date: August 17, 2026 (Form 8-K, Item 7.01 - Regulation FD Disclosure).
• Exhibits: Press release dated August 17, 2026 filed as Exhibit 99.1; Interactive XBRL cover page included as Exhibit 104.

Why It Matters Board appointments are governance events investors track because they can affect oversight and strategic direction. This 8-K formally notifies the market of the new director; investors should review the linked press release for Dr. Brosgart’s background, committee assignments, and any related disclosures to assess potential impact. No other material financial information or executive departures were reported in this filing.